Astellas Pharma and Pfizer announced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 Prosper trial. The FDA action broadens the indication for Xtandi to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC.
This approval makes Xtandi the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC. Xtandi was first approved by the FDA in 2012 for the treatment of patients with metastatic CRPC who had previously received docetaxel, and was granted approval in 2014 for chemotherapy-naïve men with metastatic CRPC.
“With today’s approval, there is now a new option for men with non-metastatic CRPC, who are in between the failure of androgen deprivation therapy resulting in CRPC and the onset of metastatic disease,” said Jonathan Simons, M.D., Prostate Cancer Foundation president and CEO. “As a foundation that drives research aimed at improving patient outcomes, it is exciting to see approvals like this, which are vital to help address unmet patient needs.”
The updated label is based on results from the Phase 3 Prosper trial, which demonstrated that the use of Xtandi plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastasis or death compared to ADT alone in men with non-metastatic CRPC. The median for the primary endpoint, metastasis-free survival (MFS), was 36.6 months for men who received Xtandi plus ADT compared to 14.7 months with ADT alone (N=1401; HR=0.29 [95 percent CI: 0.24-0.35]; p<0.0001).
The most common adverse reactions (greater than or equal to 10 percent) that occurred more frequently (greater than or equal to 2 percent over placebo) in Xtandi plus ADT-treated patients were: asthenic conditions (40 percent vs 20 percent), hot flush (13 percent vs 7.7 percent), hypertension (12 percent vs 5.2 percent), dizziness (12 percent vs 5.2 percent), nausea (11 percent vs 8.6 percent) and fall (11 percent vs 4.1 percent).
Grade 3 or higher adverse reactions were reported in 31 percent of men treated with Xtandi plus ADT and in 23 percent of men treated with ADT alone. Data from the Prosper study were presented at the 2018 Genitourinary Cancers Symposium (ASCO GU) in February and published in the New England Journal of Medicine in June.
“Reducing the risk of disease progression is an important treatment goal in castration-resistant prostate cancer, since the disease becomes harder to treat as it advances,” said Andy Schmeltz, global president, Oncology, Pfizer. “With Xtandi, men with CRPC now have a clinically proven treatment option that reduces the risk of metastasis. This approval delivers on the potential for Xtandi to help men at an earlier stage of the disease, and we are continuing to evaluate the medicine in an extensive development program across additional prostate cancer populations.”
“This approval is important progress for men with CRPC, who now have Xtandi as a treatment option regardless of whether or not they have detectable metastatic disease,” said Steven Benner, M.D., senior vice president and global therapeutic area head, Oncology Development, Astellas. “Xtandi is a standard of care in the treatment of men with metastatic CRPC and has been prescribed to more than 250,000 men worldwide since its initial approval in 2012. The expanded indication based on the Prosper data builds on the body of evidence for Xtandi.”
(Source: Astellas Pharma Inc.)
Filed Under: Drug Discovery